Xenon Pharmaceuticals Inc. (XENE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Xenon Pharmaceuticals reported revenue of $7.5M. Net income was -$345.9M (a -4612.1% net margin), or -$4.36 per diluted share. Operating margin was -4974.3%. Operating activities generated -$279.1M of cash, leaving -$279.9M of free cash flow. At fiscal year end, Xenon Pharmaceuticals held $633.2M in total assets against $51.4M in total liabilities, including $199.2M of cash and equivalents.
Open the full interactive Xenon Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Xenon Pharmaceuticals Key Stats
| Share Price | $34.42 |
|---|---|
| Market Cap | $3.43B |
| 52-Week Range | $34.42 – $70.96 |
| Shares Outstanding | 99.6 million (basic, 2026 Q2) |
Xenon Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $32.2M | $18.4M | $9.4M | $0 | $0 | $7.5M |
| Operating Income | -$31.3M | -$79.0M | -$129.1M | -$214.1M | -$279.3M | -$373.1M |
| Pre-Tax Income | -$29.1M | -$78.9M | -$125.3M | -$182.7M | -$238.4M | -$344.9M |
| Income Tax | -$257,000 | -$6,000 | $118,000 | -$292,000 | -$4.1M | $1.0M |
| Net Income | -$28.8M | -$78.9M | -$125.4M | -$182.4M | -$234.3M | -$345.9M |
| Diluted EPS | -$0.81 | -$1.77 | -$2.06 | -$2.73 | -$3.01 | -$4.36 |
Xenon Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$90.9M | -$105.3M | -$102.3M | -$110.7M |
| Diluted EPS | -$1.15 | -$1.33 | -$1.17 | -$1.11 |
Xenon Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $45.0M | $175.7M | $57.2M | $148.6M | $142.7M | $199.2M |
| Current Assets | $181.8M | $559.0M | $600.3M | $645.0M | $635.3M | $560.6M |
| Total Assets | $189.2M | $572.0M | $754.1M | $964.8M | $798.1M | $633.2M |
| Current Liabilities | $14.8M | $14.3M | $22.7M | $27.3M | $35.6M | $41.8M |
| Total Liabilities | $17.8M | $22.0M | $32.6M | $36.9M | $43.2M | $51.4M |
| Shareholders' Equity | $171.4M | $550.0M | $721.5M | $927.9M | $754.9M | $581.8M |
Xenon Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$48.1M | -$69.5M | -$98.4M | -$145.3M | -$181.4M | -$279.1M |
| Cash From Investing | -$16.8M | -$246.8M | -$296.0M | -$117.2M | $165.0M | $218.0M |
| Cash From Financing | $85.8M | $447.5M | $278.5M | $353.5M | $12.1M | $117.1M |
| Free Cash Flow | -$50.8M | -$71.6M | -$101.3M | -$150.9M | -$184.5M | -$279.9M |
Figures from Xenon Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Xenon Pharmaceuticals financials page for every line item.
Xenon Pharmaceuticals Company Profile
| Ticker | XENE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Burnaby |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001582313 |
Frequently Asked Questions
What was Xenon Pharmaceuticals' revenue in fiscal 2025?
Xenon Pharmaceuticals (XENE) reported revenue of $7.5M for fiscal 2025.
What is Xenon Pharmaceuticals' annual revenue history?
Xenon Pharmaceuticals' annual revenue by fiscal year: 2020: $32.2M; 2021: $18.4M; 2022: $9.4M; 2023: $0; 2024: $0; 2025: $7.5M.
What was Xenon Pharmaceuticals' net income in fiscal 2025?
Xenon Pharmaceuticals reported net income of -$345.9M for fiscal 2025.
What was Xenon Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Xenon Pharmaceuticals' diluted EPS was -$4.36 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Xenon Pharmaceuticals generate in fiscal 2025?
Xenon Pharmaceuticals generated -$279.9M of free cash flow in fiscal 2025.
What was Xenon Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Xenon Pharmaceuticals reported revenue of $0.
How many shares of Xenon Pharmaceuticals are outstanding?
Xenon Pharmaceuticals reported a weighted average of 99.6 million basic shares outstanding in 2026 Q2.
What is Xenon Pharmaceuticals' market cap?
Based on its latest closing price, Xenon Pharmaceuticals (XENE) has a market capitalization of about $3.43B.
When does Xenon Pharmaceuticals' fiscal year end?
Xenon Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Xenon Pharmaceuticals headquartered?
Xenon Pharmaceuticals lists its business address in Burnaby in its SEC filings.